Why Abzena?
Our focused approach.
Generation of early-stage product from fast stable cell line pools enables us to confirm the Quality Target Product Profile (QTPP). In parallel, this material can be used to initiate formulation development and analytical method development, taking these key activities off the critical path. Material from stable cell line pools can also help accelerate process development for antibody-drug conjugates.
We have developed multiple cell lines that have progressed from process development into manufacture and through clinical trials. With years of experience in providing cell line development services, our team has successfully expressed biologics including antibodies, antibody fragments, bispecific antibodies, fusion proteins, growth factors and vaccines.
Find out how our enhanced CLD solution provides the foundation of biopharmaceutical development success and mitigates risk. For molecules such as mAbs, Fabs and Fc fusions, we streamline timelines using our AbZelectPRO™ platform methodology. For novel and complex molecules, our AbZelectPRO™ platform also allows us to design and develop a rapid, robust approach to your program. Download your copy of our info sheet here.